Frontiers in Endocrinology (Nov 2023)

The effects of gonadotropin-releasing hormone agonist on final adult height among girls with early and fast puberty

  • Chin-Hui Tseng,
  • Chin-Hui Tseng,
  • Yann-Jinn Lee,
  • Yann-Jinn Lee,
  • Yann-Jinn Lee,
  • Yann-Jinn Lee,
  • Yann-Jinn Lee,
  • Chi-Yu Huang,
  • Yi-Lei Wu,
  • Lu-Ting Wang,
  • Chao-Hsu Lin,
  • Chao-Hsu Lin,
  • Bi-Wen Cheng,
  • Fu-Sung Lo,
  • Fu-Sung Lo,
  • Yu-Jun Chang,
  • Wei-Hsin Ting,
  • Wei-Hsin Ting

DOI
https://doi.org/10.3389/fendo.2023.1271395
Journal volume & issue
Vol. 14

Abstract

Read online

IntroductionThis study aimed to explore the impact of gonadotropin-releasing hormone agonists (GnRHa) on final adult height (FAH) in girls with early and fast puberty.MethodsA retrospective study was conducted by reviewing data from the medical records of the Pediatric Endocrinology Clinics between January 1, 2010, and December 31, 2020, at MacKay Children’s Hospital. The treatment group included 109 patients who received 3.75 mg monthly for at least 1 year, whereas the control group consisted of 95 girls who received no treatment.ResultsThe treatment group was significantly older at the time of inclusion(chronological age (CA1), treatment vs. control, 8.7 vs. 8.4 years, p < 0.001), had a more advanced bone age (BA) (BA1, 11.5 vs. 10.8 years, p < 0.001), BA1-CA1 (2.7 vs. 2.2 years, p < 0.001), and shorter predicted adult height (PAH1) (153.3 vs. 157.1 cm, p = 0.005) that was significantly lower than their target height (Tht)(PAH1-Tht, −3.9 vs. −1.3 cm, p = 0.039). The FAHs of the GnRHa and the control group were similar (157.0 vs. 156.7 cm, p = 0.357) and were not significantly different from their Tht (FAH vs. Tht in the GnRHa group, 157.0 vs. 157.0 cm; control group, 156.7 vs. 157.0 cm). In the subgroup analysis, FAH was significantly higher after GnRHa treatment in those with PAH1 less than 153 cm and Tht (154.0 vs. 152.0 cm, p = 0.041), and those whose CA1 was between 8 and 9 years (158.0 vs. 155.4 cm, p = 0.004). We defined satisfactory FAH outcome as FAH-PAH1≥5 cm and significant factors were GnRHa therapy, PAH1 shorter than their Tht, age younger than 9 years, and faster growth velocity during the first year.DiscussionGnRHa is effective in restoring the Tht in some early and fast pubertal girls, especially in those with poorly PAH (PAH lower than 153 cm and shorter than their target height). A younger age at initiation of treatment and a faster growth velocity during treatment are associated with a better height gain.

Keywords